Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated

Hepatol Int. 2024 Apr;18(2):704-705. doi: 10.1007/s12072-023-10611-z. Epub 2023 Nov 9.

Authors

Sai Li^{1

2}, Yong Li³

Affiliations

¹ Interventional Radiology Center, Department of Radiology, The Third Xiangya Hospital of Central South Hospital, Changsha, 410005, Hunan, China.
² Interventional Radiology Center, Department of Radiology, Xiangya Hospital Central South University, Changsha, 410005, Hunan, China.
³ Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, 410005, Hunan, China. stanlee@csu.edu.cn.

PMID: 37943415
DOI: 10.1007/s12072-023-10611-z

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Hepatocellular* / pathology
Carcinoma, Hepatocellular* / therapy
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Phenylurea Compounds / therapeutic use
Quinolines*

Substances

lenvatinib
Phenylurea Compounds
Quinolines